Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07432789
Recruiting Not applicable

Metrological Properties of a Digital Motion Analysis Research Application for Assessing the Motor Abilities and Performance of Children With Cerebral Palsy

NCT07432789 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-03-18
Last updated
2026-04-17

Condition(s) studied

Cerebral Palsy

Investigational drug(s) / intervention(s)

Assessment of functional abilitiesChildren's self-questionnairesParent self-assessment questionnairesSemi-structured interviewAssessment of functional abilities

Assessment of functional abilities: Gold standard

Children's self-questionnaires: ABILOCO-Kids

Parent self-assessment questionnaires: GOAL

Semi-structured interview: Interview

Assessment of functional abilities: Application

Study summary

Cerebral palsy is a common neurological disorder that is the leading cause of motor disability in children. It causes significant motor impairments, affecting various aspects such as fine and gross motor skills, as well as locomotion, which has a major impact on the quality of life of affected children. It is therefore essential to characterize these functional impairments in order to guide clinical decisions and maximize the motor function of affected children.

Currently, the assessment of motor function is based on physical examinations and functional scales, such as the Gross Motor Function Classification System, which is specifically designed to assess children with CP. However, movement analysis using optoelectronic systems is considered the gold standard for this assessment, even though these systems have notable limitations (expensive installation, time-consuming use, and use only in a clinical environment, making it difficult to assess motor skills in children's everyday lives). In order to establish a comprehensive and personalized functional diagnosis, it is crucial to evaluate other fundamental motor tasks such as running, jumping, object control, and balance tasks. Recently, innovative markerless motion analysis technologies have been developed that allow analysis using smartphones or tablets outside of healthcare facilities. Therefore, developing an application dedicated to motion analysis for children with cerebral palsy that is easy to access and can be used frequently could yield many significant benefits.

Eligibility

Sex
ALL
Min age
6 Years
Max age
18 Years
Healthy volunteers
Accepted
Inclusion Criteria: Common to both groups: * Obtaining free and informed consent from the child and at least one parent * Children of all genders aged 6 to 18 * Children affiliated with or beneficiaries of a social security system For the Cerebral Palsy group: * Medical diagnosis of CP according to the SCPE (Surveillance of Cerebral Palsy in Europe) definition; * Unilateral and bilateral impairment; * Gross Motor Function Classification System (GMFCS) = I to III; * No major cognitive or visual impairments that limit the performance of motor tasks For the control group: \- Children free from any disease Other volunteers included in the protocol (qualitative analysis only (parents and clinicians)): * Parent(s) of children with CP included in this study; * Healthcare professionals and researchers involved in monitoring children with CP and/or evaluating the research application within the framework of this study Exclusion Criteria: Common to both groups: * Participants or parent(s) of participants who do not speak French * Children subject to legal protection measures * Pregnant or breastfeeding participants For the Cerebral Palsy group: * Presence of a cause of neuro-orthopedic disorders other than CP * Limiting pain * Surgical procedures performed less than 6 months prior to inclusion in the study * Any other functional medical intervention that took place 3 months prior to inclusion in the study (e.g., botulinum toxin injections, plaster casts, etc.) * Medical or surgical interventions planned between visit 1 and visit 2 * Children with a condition other than cerebral palsy that affects their walking ability

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Chu Dijon Bourgogne Dijon France Recruiting

More Centre Hospitalier Universitaire Dijon trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07432789 on ClinicalTrials.gov ↗ ← All trials in France